Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria | Zendy

Brahm H. Segal | Zendy; Raoul Herbrecht | Zendy; David A. Stevens | Zendy; Luis OstroskyZeichner | Zendy; Jack D. Sobel | Zendy; Claudio Viscoli | Zendy; Thomas J. Walsh | Zendy; Johan Maertens | Zendy; Thomas F. Patterson | Zendy; John R. Perfect | Zendy; B. Dupont | Zendy; John R. Wingard | Zendy; Thierry Calandra | Zendy; Carol A. Kauffman | Zendy; John R. Graybill | Zendy; Lindsey R. Baden | Zendy; Peter G. Pappas | Zendy; John E. Bennett | Zendy; Dimitrios P. Kontoyiannis | Zendy; Catherine Cordonnier | Zendy; M. A. Viviani | Zendy; Jacques Billé | Zendy; Nikolaos G. Almyroudis | Zendy; L. Joseph Wheat | Zendy; Wolfgang Graninger | Zendy; Eric J. Bow | Zendy; Steven M. Holland | Zendy; Bart Jan Kullberg | Zendy; William E. Dismukes | Zendy; B.E. de Pauw | Zendy

Open Access

Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria

Author(s) -

Brahm H. Segal,

Raoul Herbrecht,

David A. Stevens,

Luis OstroskyZeichner,

Jack D. Sobel,

Claudio Viscoli,

Thomas J. Walsh,

Johan Maertens,

Thomas F. Patterson,

John R. Perfect,

B. Dupont,

John R. Wingard,

Thierry Calandra,

Carol A. Kauffman,

John R. Graybill,

Lindsey R. Baden,

Peter G. Pappas,

John E. Bennett,

Dimitrios P. Kontoyiannis,

Catherine Cordonnier,

M. A. Viviani,

Jacques Billé,

Nikolaos G. Almyroudis,

L. Joseph Wheat,

Wolfgang Graninger,

Eric J. Bow,

Steven M. Holland,

Bart Jan Kullberg,

William E. Dismukes,

B.E. de Pauw

Publication year - 2008

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/590566

Subject(s) - medicine , clinical trial , coccidioides , coccidioides immitis , intensive care medicine , antifungal , cryptococcus neoformans , aspergillosis , cryptococcosis , cancer , histoplasma , disease , histoplasmosis , pathology , immunology , histoplasma capsulatum , dermatology , biology , microbiology and biotechnology

Invasive fungal diseases (IFDs) have become major causes of morbidity and mortality among highly immunocompromised patients. Authoritative consensus criteria to diagnose IFD have been useful in establishing eligibility criteria for antifungal trials. There is an important need for generation of consensus definitions of outcomes of IFD that will form a standard for evaluating treatment success and failure in clinical trials. Therefore, an expert international panel consisting of the Mycoses Study Group and the European Organization for Research and Treatment of Cancer was convened to propose guidelines for assessing treatment responses in clinical trials of IFDs and for defining study outcomes. Major fungal diseases that are discussed include invasive disease due to Candida species, Aspergillus species and other molds, Cryptococcus neoformans, Histoplasma capsulatum, and Coccidioides immitis. We also discuss potential pitfalls in assessing outcome, such as conflicting clinical, radiological, and/or mycological data and gaps in knowledge.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research